{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29&page=4",
    "query": {
      "intervention": "Placebo (Capsule/Tablet)",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 678,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T14:02:35.413Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06619847",
      "title": "A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "VX-993",
          "type": "DRUG"
        },
        {
          "name": "HB/APAP",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to VX-993)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to HB/APAP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 367,
      "start_date": "2024-10-29",
      "completion_date": "2025-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 14,
      "location_summary": "Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619847"
    },
    {
      "nct_id": "NCT00946569",
      "title": "A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "JNJ39758979",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 116,
      "start_date": "2009-08",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Cypress, California • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00946569"
    },
    {
      "nct_id": "NCT04308304",
      "title": "MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "MK-1942",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2021-02-16",
      "completion_date": "2022-05-18",
      "has_results": true,
      "last_update_posted_date": "2024-08-15",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 4,
      "location_summary": "Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04308304"
    },
    {
      "nct_id": "NCT07046806",
      "title": "Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)",
        "Angioedema",
        "Bradykinin-mediated Angioedema",
        "C1 Inhibitor Deficiency"
      ],
      "interventions": [
        {
          "name": "Deucrictibant XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator to XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Deucrictibant 20 mg capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator to 20 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute for Asthma and Allergy",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-03-10",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 1,
      "location_summary": "Wheaton, Maryland",
      "locations": [
        {
          "city": "Wheaton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07046806"
    },
    {
      "nct_id": "NCT04624243",
      "title": "Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Elpipodect",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo to MK-8189",
          "type": "DRUG"
        },
        {
          "name": "Placebo to risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 499,
      "start_date": "2020-12-15",
      "completion_date": "2024-06-21",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 35,
      "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04624243"
    },
    {
      "nct_id": "NCT01280591",
      "title": "Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium 440 mg (BAYH6689)",
          "type": "DRUG"
        },
        {
          "name": "DPH 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "12 Years to 45 Years"
      },
      "enrollment_count": 712,
      "start_date": "2010-10",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 2,
      "location_summary": "Austin, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01280591"
    },
    {
      "nct_id": "NCT01372150",
      "title": "A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "desvenlafaxine succinate sustained release",
          "type": "DRUG"
        },
        {
          "name": "fluoxetine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 340,
      "start_date": "2011-11-17",
      "completion_date": "2015-03-20",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 41,
      "location_summary": "Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372150"
    },
    {
      "nct_id": "NCT01244490",
      "title": "Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Extended-release Guanfacine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 338,
      "start_date": "2011-01-17",
      "completion_date": "2013-05-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Maitland, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Rochester Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01244490"
    },
    {
      "nct_id": "NCT01210560",
      "title": "Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autosomal Dominant Polycystic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Tolvaptan MR",
          "type": "DRUG"
        },
        {
          "name": "Tolvaptan IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 25,
      "start_date": "2010-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01210560"
    },
    {
      "nct_id": "NCT04335591",
      "title": "Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 75 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablet to match 200 mg linzagolix tablet",
          "type": "DRUG"
        },
        {
          "name": "Add-back capsule (E2 1 mg / NETA 0.5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsule to match Add-back capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kissei Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 356,
      "start_date": "2020-03-05",
      "completion_date": "2022-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-02T14:02:35.413Z",
      "location_count": 8,
      "location_summary": "Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04335591"
    }
  ]
}